ADDvise Group AB (publ) has mandated Pareto Securities AB to arrange a series of fixed income investor meetings starting on 22 November 2022. Subject to inter alia market conditions, a subsequent bond issue of SEK 150 million under the company's existing senior secured bond loan with ISIN SE0015222088 (the "Bonds") may follow. The subsequent bond issue is fully subscribed based on substantial pre-commitments and indications from certain investors.
The net proceeds from the contemplated subsequent bond issue will be used to part-finance the acquisition of CliniChain Holding B.V. or any other acquisition replacing the acquisition of CliniChain Holding B.V.
In connection with the contemplated subsequent bond issue, the company will request approval from holders of the Bonds for certain amendments to the terms and conditions of the Bonds in order to inter alia permit the contemplated subsequent bond issue. Additional information pertaining to the written procedure is set out in a separate press release as well as in the relevant notice of written procedure.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
Hanna Myhrman, General Counsel
+46 709-82 92 23
This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 21 November 2022 at 17:45 CET.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business – both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.